---
audienceLevel: patient
cancerTypes:
- liver
- kidney
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Cabozantinib-S-Malate - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/cabozantinib-s-malate
version: v1
---

# Cabozantinib-S-Malate - NCI

# Cabozantinib-S-Malate

Placeholder slot

(KA-boh-ZAN-tih-nib ... MA-layt)

Cabozantinib-s-malate works by blocking proteins that signal cancer cells to divide. It also blocks proteins that signal the growth of new blood vessels that supply oxygen and nutrients needed for tumor growth. Blocking these signals keeps cancer cells from growing and spreading to other parts of the body. Cabozantinib-s-malate is a type of targeted therapy drug called a kinase inhibitor. It is a small-molecule drug (a drug that can enter cells easily).

US Brand Name(s)

Cabometyx
Cometriq

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=CABOZANTINIB&pagesize=20&page=1&audience=consumer)

## Use in Cancer

Cabozantinib-s-malate
is approved
to treat:

- **[Differentiated thyroid cancer](/Common/PopUps/popDefinition.aspx?id=806206&version=Patient&language=English)** that has spread. It is used in adults and children aged 12 years and older who cannot receive [radioactive iodine](/Common/PopUps/popDefinition.aspx?id=45855&version=Patient&language=English) and whose cancer got worse after [VEGF](/Common/PopUps/popDefinition.aspx?id=44474&version=Patient&language=English) [receptor](/Common/PopUps/popDefinition.aspx?id=44958&version=Patient&language=English)-[targeted therapy](/Common/PopUps/popDefinition.aspx?id=270742&version=Patient&language=English). This use is approved for the Cabometyx brand of cabozantinib-s-malate.
- **[Hepatocellular carcinoma](/Common/PopUps/popDefinition.aspx?id=46363&version=Patient&language=English)** (a type of [liver cancer](/Common/PopUps/popDefinition.aspx?id=44242&version=Patient&language=English)). It is used in patients who have already been treated with [sorafenib](/Common/PopUps/popDefinition.aspx?id=509041&version=Patient&language=English). This use is approved for the Cabometyx brand of cabozantinib-s-malate.
- **[Medullary thyroid cancer](/Common/PopUps/popDefinition.aspx?id=44550&version=Patient&language=English)** that has gotten worse and has spread to other parts of the body. This use is approved for the Cometriq brand of cabozantinib-s-malate.
- **[Neuroendocrine tumor](/Common/PopUps/popDefinition.aspx?id=44904&version=Patient&language=English)** of the [pancreas](/Common/PopUps/popDefinition.aspx?id=46254&version=Patient&language=English) or another organ that is [well-differentiated](/Common/PopUps/popDefinition.aspx?id=774690&version=Patient&language=English), has spread, and cannot be removed by surgery. It is used in adults and children aged 12 years and older whose cancer has been treated. This use is approved for the Cabometyx brand of cabozantinib-s-malate.
- **[Renal cell carcinoma](/Common/PopUps/popDefinition.aspx?id=661352&version=Patient&language=English)** (a type of [kidney cancer](/Common/PopUps/popDefinition.aspx?id=444995&version=Patient&language=English)) that is [advanced](/Common/PopUps/popDefinition.aspx?id=478743&version=Patient&language=English). It is either used with [nivolumab](/Common/PopUps/popDefinition.aspx?id=767747&version=Patient&language=English) as the first therapy or alone. This use is approved for the Cabometyx brand of cabozantinib-s-malate.

Cabozantinib-s-malate
is also being studied in the treatment of other types of
cancer.

## More About Cabozantinib-S-Malate

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/461103) - Detailed scientific definition and other names for this drug.

MedlinePlus Information on [Cabozantinib-S-Malate (for thyroid cancer)](https://medlineplus.gov/druginfo/meds/a613015.html) and [Cabozantinib-S-Malate (for renal cell carcinoma)](https://medlineplus.gov/druginfo/meds/a616037.html) - Lay language summaries of important information about this drug that may include the following:

- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

## Research Results and Related Resources

[What Comes after NCI-MATCH? NCIâ€™s New Precision Medicine Cancer Trials](https://www.cancer.gov/news-events/cancer-currents-blog/2023/new-nci-precision-medicine-trials)

[Targeted Therapy to Treat Cancer](https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Cabozantinib S-malate](https://www.cancer.gov/research/participate/clinical-trials/intervention/C97938) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
